{"id":754664,"date":"2023-05-04T06:04:08","date_gmt":"2023-05-04T10:04:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/"},"modified":"2023-05-04T06:04:08","modified_gmt":"2023-05-04T10:04:08","slug":"reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/","title":{"rendered":"Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CUPERTINO, Calif., May  04, 2023  (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at three upcoming scientific conferences to be held in May 2023.<\/p>\n<p align=\"justify\">Details for the conferences can be found below:<\/p>\n<p align=\"justify\">\n        <strong>International Societies for Investigative Dermatology (ISID) Meeting 2023<\/strong><br \/>\n        <br \/>\n        <em>Brilaroxazine topical liposomal-gel formulation displays efficacy in the imiquimod-induced\u00a0<\/em><br \/>\n        <em>psoriatic BALB\/c mouse model<\/em><br \/>\n        <br \/>Date: May 12, 2023<br \/>Time: 6:10 \u2013 7:40pm JST<br \/>Presenters: Laxminarayan Bhat<br \/>Location: Keio Plaza Hotel, Tokyo, Japan<\/p>\n<p align=\"justify\">\n        <strong>American Society for Pharmacology and Experimental Therapeutics (ASPET) 2023<\/strong><br \/>\n        <br \/>Poster Presentation: <em>CYP3A inhibition and induction exert limited effects on brilaroxazine pharmacokinetic<\/em><br \/>Date: Friday, May 19, 2023<br \/>Time: 5:00-7:00pm ET<br \/>Presenters: Laxminarayan Bhat <br \/>Location: St. Louis Union Station Hotel, St. Louis, MA, USA<\/p>\n<p align=\"justify\">Poster Presentation: <em>Single-dose Brilaroxazine Pharmacokinetics, Metabolism, and Excretion Profile in Animals and Humans<\/em><br \/>Date: Saturday, May 20, 2023 <br \/>Time: 5:00-7:00pm ET<br \/>Presenters: Laxminarayan Bhat<br \/>Location: St. Louis Union Station Hotel, St. Louis, MA, USA<\/p>\n<p align=\"justify\">\n        <strong>American Thoracic Society (ATS) 2023<\/strong><br \/>\n        <br \/>Poster Presentation: <em>Brilaroxazine Efficacy in a Bleomycin-induced Rodent Model of Idiopathic Pulmonary Fibrosis<\/em><br \/>Date: Wednesday, May 24, 2023<br \/>Time: 8:00-10:00am ET<br \/>Presenters: Laxminarayan Bhat<br \/>Location: Walter E. Washington Convention Center, Washington, DC, USA<\/p>\n<p align=\"justify\">\n        <strong>About Reviva\u2019s Lead Drug Candidate Brilaroxazine<\/strong><br \/>\n        <strong>\u00a0<\/strong><br \/>\n        <br \/>Brilaroxazine is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms. In a multinational, multicenter, double-blind Phase 2 study in 234 patients with acute schizophrenia or schizoaffective disorder, brilaroxazine\u00a0met its primary endpoint, reducing Positive and Negative Syndrome Scale (PANSS) total score and demonstrating statistically significant improvement of overall drug treatment outcomes using Clinical Global Impression (CGI) scale and for secondary endpoints evaluating social functioning, and positive and negative symptoms, and directional improvements for depression and cognition. In this completed Phase 2 study, brilaroxazine met all safety endpoints with no weight gain, no increase in blood sugar and lipids, and no cardiac or endocrine adverse effects compared to placebo. Positive data from a clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects supports no clinically significant interaction when combined with a CYP3A4 inhibitor. A full battery of regulatory compliant toxicology and safety pharmacology studies has been completed for brilaroxazine. The U.S. Food and Drug Administration (FDA) has agreed to consider a potential superior safety label claim if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 study in patients with schizophrenia. Reviva intends to develop brilaroxazine\u00a0for other neuropsychiatric indications including bipolar disorder, major depressive disorder (MDD) and attention-deficit\/hyperactivity disorder (ADHD).<\/p>\n<p align=\"justify\">Additionally, brilaroxazine\u00a0has shown promising efficacy for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) with mitigation of lung fibrosis and inflammation in translational animal models. Reviva believes brilaroxazine has the potential to delay disease progression in PAH and IPF and intends to develop brilaroxazine for these pulmonary indications. Brilaroxazine\u00a0has already received Orphan Drug Designation by the U.S. FDA for the treatment of these conditions.<\/p>\n<p align=\"justify\">To learn more about the clinical and preclinical data available for brilaroxazine, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ARD0Qm6RyMMhyhNAzKBQsihfhfEyVMBSXp0LdEzXkCCtutFsCozKOKIssTcWKe-bn4Mbk1Fu3hj08FmZ1ucT3ju6CGqATJEJqYIkNUvd5dw_JLpg0aEE7mSInZGVeaHbIP0fCSKlv7Eq4L4lEJ3HxoXH9W0EWjvHh1EFCJi8x8uAsnxan87kvxVegJI9qApw0pr9GiZc6oB4q0FMfF2QBMTlV_W77TUG0zHnU-Q4S0yp5sK2wQSr_a1ogb4GxrZX6rItVKiYp_vmZsUXpYJweeG8fvBXWtGZVmqT-XfnwX4=\" rel=\"nofollow noopener\" target=\"_blank\">revivapharma.com\/publications<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Reviva\u00a0<\/strong><br \/>\n        <br \/>Reviva is a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva\u2019s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva\u2019s pipeline currently includes two drug candidates, brilaroxazine and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine\u00a0and RP1208 in the United States (U.S.), Europe, and several other countries.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company\u2019s RECOVER Phase 3 trial, including expectations therefor and the timing of topline data, the Company\u2019s expectations regarding the anticipated clinical profile of its product candidates, including statements regarding anticipated efficacy profile, product development, clinical and regulatory approval pathways, timelines expenses, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management\u2019s current beliefs and assumptions.<\/p>\n<p align=\"justify\">These statements may be identified by the use of forward-looking expressions, including, but not limited to, \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwould\u201d and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company\u2019s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and the Company\u2019s other filings from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong><br \/>\n        <br \/>Reviva Pharmaceuticals Holdings, Inc.<br \/>Laxminarayan Bhat, PhD\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2PoumCy2Wa7_6FCPI0NiHrXDpS1-T0GMX2mnA2PcLpNcLrn9-W_spBneEcgSK-SluZp9Chu1005nYUv5AwgSwmg_i32BMFfUEKreNkSIVAo=\" rel=\"nofollow noopener\" target=\"_blank\">www.revivapharma.com<\/a><\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>LifeSci Advisors, LLC<br \/>Bruce Mackle<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4jMaN2t668Vy2p34HfOjz2eNs3CAhuFwLHlwJz-Nyr94GfXY2t6ugPaz8XSigJH88ycNzLs4zTsk1Y-vMb_WHSrMnCDPDk44Zq_yh2buYb-_Dsnvu1Jht9-3EKub-wzspU21JQj2Qa0SHhxA3_No-DnA7SUfVpz2Aa_ZmARsuHFnOJAlMUNgN3n3240q-ugSfySxNsxaL2TREjZQcoKF8vU3tTUSN_rotlOTmss7HCVJk1f2PEK65KlCXVYIR915t-J-spTVbq1kQL5g_Nnd9CMvLJLvyMcYYouBZcBrjz4=\" rel=\"nofollow noopener\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/p>\n<p>RedChip Companies, Inc.<br \/>Todd McKnight<br \/>(917) 349.2175<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t3GoPLiK3PvGyHQn8AaRyQPg_L6yzX2Z5_KBoCz5N5Cu7y2jdIlHMIchwsayyO_nuU0Hy9-Tbumd1Ywd3RyuAA==\" rel=\"nofollow noopener\" target=\"_blank\">RVPH@redchip.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ3MyM1NTczNDMwIzUwMDA3NTM4MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTNhZmZhMjItMWNjZC00ZTI1LWExM2EtYjAzNzhlZWI3MWNkLTUwMDA3NTM4MQ==\/tiny\/Reviva-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CUPERTINO, Calif., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at three upcoming scientific conferences to be held in May 2023. Details for the conferences can be found below: International Societies for Investigative Dermatology (ISID) Meeting 2023 Brilaroxazine topical liposomal-gel formulation displays efficacy in the imiquimod-induced\u00a0 psoriatic BALB\/c mouse model Date: May 12, 2023Time: 6:10 \u2013 7:40pm JSTPresenters: Laxminarayan BhatLocation: Keio Plaza Hotel, Tokyo, Japan American Society for Pharmacology and Experimental Therapeutics &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754664","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CUPERTINO, Calif., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at three upcoming scientific conferences to be held in May 2023. Details for the conferences can be found below: International Societies for Investigative Dermatology (ISID) Meeting 2023 Brilaroxazine topical liposomal-gel formulation displays efficacy in the imiquimod-induced\u00a0 psoriatic BALB\/c mouse model Date: May 12, 2023Time: 6:10 \u2013 7:40pm JSTPresenters: Laxminarayan BhatLocation: Keio Plaza Hotel, Tokyo, Japan American Society for Pharmacology and Experimental Therapeutics &hellip; Continue reading &quot;Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T10:04:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ3MyM1NTczNDMwIzUwMDA3NTM4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023\",\"datePublished\":\"2023-05-04T10:04:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\\\/\"},\"wordCount\":969,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQ3MyM1NTczNDMwIzUwMDA3NTM4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\\\/\",\"name\":\"Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQ3MyM1NTczNDMwIzUwMDA3NTM4MQ==\",\"datePublished\":\"2023-05-04T10:04:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQ3MyM1NTczNDMwIzUwMDA3NTM4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQ3MyM1NTczNDMwIzUwMDA3NTM4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/","og_locale":"en_US","og_type":"article","og_title":"Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023 - Market Newsdesk","og_description":"CUPERTINO, Calif., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at three upcoming scientific conferences to be held in May 2023. Details for the conferences can be found below: International Societies for Investigative Dermatology (ISID) Meeting 2023 Brilaroxazine topical liposomal-gel formulation displays efficacy in the imiquimod-induced\u00a0 psoriatic BALB\/c mouse model Date: May 12, 2023Time: 6:10 \u2013 7:40pm JSTPresenters: Laxminarayan BhatLocation: Keio Plaza Hotel, Tokyo, Japan American Society for Pharmacology and Experimental Therapeutics &hellip; Continue reading \"Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T10:04:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ3MyM1NTczNDMwIzUwMDA3NTM4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023","datePublished":"2023-05-04T10:04:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/"},"wordCount":969,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ3MyM1NTczNDMwIzUwMDA3NTM4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/","name":"Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ3MyM1NTczNDMwIzUwMDA3NTM4MQ==","datePublished":"2023-05-04T10:04:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ3MyM1NTczNDMwIzUwMDA3NTM4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ3MyM1NTczNDMwIzUwMDA3NTM4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-three-upcoming-scientific-conferences-in-may-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754664"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754664\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}